Not Yet RecruitingPhase 2ketamine

Quelling of Excitotoxicity in Acute Stroke With Ketamine

Sponsored by Lower Merion Neurology Research Foundation

NCT ID
NCT03223220
Target Enrollment
120 participants
Start Date
2024-07-01
Est. Completion
2027-12-31

About This Study

The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.

Conditions Studied

Acute Ischemic Stroke

Interventions

  • Ketamine
  • Normal Saline
  • Midazolam injection

Eligibility

Age:18 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

1. All patients who are 18 years or older, presenting or admitted to the study site with acute ischemic stroke, up to 24 hours since their last known well time
2. An MRI evidence of acute ischemic infarct on the diffusion-weighted imaging with ADC correlate
3. Pre-stroke modified Rankin scale of 0-2
4. Patient should be willing to participate in the study by providing a written consent himself/herself or through a proxy.

Exclusion Criteria:

1. Eligibility to receive IV Alteplase or intra-arterial thrombectomy/embolectomy
2. Longer than 24 hours since last known well time
3. Pre-stroke modified Rankin scale of 3 or above.
4. Pregnant or lactating females
5. Pre-existing psychiatric illness
6. Intracranial hemorrhage of any type at presentation
7. Seizure at onset of symptoms
8. Sustained uncontrolled hypertension defined as Systolic Blood pressure greater than 185 mmHg or Diastolic Blood Pressure greater than 110 mmHg, despite administration of antihypertensive medications
9. Known hypersensitivity or adverse reaction to prior administration of Ketamine
10. Inability/refusal to provide consent by the patient or through a proxy

Study Locations (1)

Lankenau Medical Center
Wynnewood, Pennsylvania, United States

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

Sudhir Aggarwal, MD, PhD
CONTACT
4844132572saggarwal@lowermerionneurology.com
View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source